Bilateral Pleural Effusions due to Pulmonary Amyloidosis as the Presenting Manifestation of Multiple Myeloma

Por Agarwal, Abhishek, Singla, Sandeep, Bansal, Meghana, Nair, Bijay
Publicado em 2012

Unilateral conjunctival AL kappa amyloidosis with trace evidence of systemic amyloidosis

Por Abdallah, Al-Ola, Westfall, Christopher, Brown, Harry, Muzaffar, Jameel, Atrash, Shebli, Nair, Bijay
Publicado em 2012

Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols

Por Nair, Bijay, Waheed, Sarah, Szymonifka, Jackie, Shaughnessy, John D., Crowley, John, Barlogie, Bart
Publicado em 2008

Cytogenetic Abnormalities in Multiple Myeloma: Poor Prognosis Linked to Concomitant Detection in Random and Focal Lesion Bone Marrow Samples and Associated with High-Risk Gene Expr...

Por Zhou, Yiming, Nair, Bijay, Shaughnessy, John D, Cartron, Marie-Astrid, Haessler, Jeff, Anaissie, Elias, van Rhee, Frits, Crowley, John, Barlogie, Bart
Publicado em 2009

Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

Por Nair, Bijay, van Rhee, Frits, Shaughnessy, John D., Anaissie, Elias, Szymonifka, Jackie, Hoering, Antje, Alsayed, Yazan, Waheed, Sarah, Crowley, John, Barlogie, Bart
Publicado em 2010

International Staging System and Metaphase Cytogenetic Abnormalities in the Era of Gene Expression Profiling Data in Multiple Myeloma Treated with Total Therapy 2 and 3 Protocols

Por Waheed, Sarah, Shaughnessy, John D, van Rhee, Frits, Alsayed, Yazan, Nair, Bijay, Anaissie, Elias, Szymonifka, Jackie, Hoering, Antje, Crowley, John, Barlogie, Bart
Publicado em 2010

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

Por Hoering, Antje, Crowley, John, Shaughnessy, John D, Hollmig, Klaus, Alsayed, Yazan, Szymonifka, Jackie, Waheed, Sarah, Nair, Bijay, van Rhee, Frits, Anaissie, Elias, Barlogie, Bart
Publicado em 2009

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamet...

Por van Rhee, Frits, Szymonifka, Jackie, Anaissie, Elias, Nair, Bijay, Waheed, Sarah, Alsayed, Yazan, Petty, Nathan, Shaughnessy, John D., Hoering, Antje, Crowley, John, Barlogie, Bart
Publicado em 2010

TP53 Deletion is Not an Adverse Feature in Multiple Myeloma Treated with Total Therapy 3

Por Shaughnessy, John D, Zhou, Yiming, Haessler, Jeff, van Rhee, Frits, Anaissie, Elias, Nair, Bijay, Waheed, Sarah, Alsayed, Yazan, Epstein, Joshua, Crowley, John, Barlogie, Bart
Publicado em 2009

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)

Por Dhodapkar, Madhav V., Sexton, Rachael, Waheed, Sarah, Usmani, Saad, Papanikolaou, Xenofon, Nair, Bijay, Petty, Nathan, Shaughnessy, John D., Hoering, Antje, Crowley, John, Orlowski, Robert Z., Barlogie, Bart
Publicado em 2014

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

Por Usmani, Saad Z., Heuck, Christoph, Mitchell, Alan, Szymonifka, Jackie, Nair, Bijay, Hoering, Antje, Alsayed, Yazan, Waheed, Sarah, Haider, Sajjad, Restrepo, Alejandro, Van Rhee, Frits, Crowley, John, Barlogie, Bart
Publicado em 2012

Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols

Por Singh, Zeba N, Jethava, Yogesh, Post, Ginell R, Alapat, Daisy, Sawyer, Jeffrey, Waheed, Sarah, Nair, Bijay, Usmani, Saad Z, Bailey, Clyde, Petty, Nathan, Van Rhee, Frits, Barlogie, Bart
Publicado no Clin Case Rep (2015)

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival

Por Nair, Bijay, Shaughnessy, John D., Zhou, Yiming, Astrid-Cartron, Marie, Qu, Pingping, van Rhee, Frits, Anaissie, Elias, Alsayed, Yazan, Waheed, Sarah, Hollmig, Klaus, Szymonifka, Jackie, Petty, Nathan, Hoering, Antje, Barlogie, Bart
Publicado em 2009

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance

Por Usmani, Saad Z., Sexton, Rachel, Hoering, Antje, Heuck, Christoph J., Nair, Bijay, Waheed, Sarah, Al Sayed, Yazan, Chauhan, Nabeel, Ahmad, Nisar, Atrash, Shebli, Petty, Nathan, van Rhee, Frits, Crowley, John, Barlogie, Bart
Publicado em 2012

High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2

Por Zhou, Yiming, Chen, Lijuan, Barlogie, Bart, Stephens, Owen, Wu, Xiaosong, Williams, David R., Cartron, Marie-Astrid, van Rhee, Frits, Nair, Bijay, Waheed, Sarah, Pineda-Roman, Mauricio, Alsayed, Yazan, Anaissie, Elias, Shaughnessy, John D.
Publicado em 2010

Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data

Por Waheed, Sarah, Mitchell, Alan, Usmani, Saad, Epstein, Joshua, Yaccoby, Shmuel, Nair, Bijay, van Hemert, Rudy, Angtuaco, Edgardo, Brown, Tracy, Bartel, Twyla, McDonald, James, Anaissie, Elias, van Rhee, Frits, Crowley, John, Barlogie, Bart
Publicado em 2013

Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Por Heuck, Christoph J, Szymonifka, Jackie, Hansen, Emily, Shaughnessy, John D., Usmani, Saad Z, van Rhee, Frits, Anaissie, Elias, Nair, Bijay, Waheed, Sarah, Alsayed, Yazan, Petty, Nathan, Bailey, Clyde, Epstein, Joshua, Hoering, Antje, Crowley, John, Barlogie, Bart
Publicado em 2012

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

Por Shaughnessy, John D., Qu, Pingping, Usmani, Saad, Heuck, Christoph J., Zhang, Qing, Zhou, Yiming, Tian, Erming, Hanamura, Ichiro, van Rhee, Frits, Anaissie, Elias, Epstein, Joshua, Nair, Bijay, Stephens, Owen, Williams, Ryan, Waheed, Sarah, Alsayed, Yazan, Crowley, John, Barlogie, Bart
Publicado em 2011

Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone

Por Li, Xin, Ling, Wen, Pennisi, Angela, Wang, Yuping, Khan, Sharmin, Heidaran, Mohammad, Pal, Ajai, Zhang, Xiaokui, He, Shuyang, Zeitlin, Andy, Abbot, Stewart, Faleck, Herbert, Hariri, Robert, Shaughnessy, John D., van Rhee, Frits, Nair, Bijay, Barlogie, Bart, Epstein, Joshua, Yaccoby, Shmuel
Publicado em 2011

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling, and clinical outcome with Total Therapy protocols

Por Usmani, Saad Z, Nair, Bijay, Qu, Pingping, Hansen, Emily, Zhang, Qing, Petty, Nathan, Waheed, Sarah, Shaughnessy, John D, Alsayed, Yazan, Heuck, Christoph J, van Rhee, Frits, Milner, Teresa, Hoering, Antje, Szymonifka, Jackie, Sexton, Rachael, Sawyer, Jeffrey, Singh, Zeba, Crowley, John, Barlogie, Bart
Publicado em 2012